stockrow
Friday 6 November 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024.
- Revenue
- +8.95%
- EPS
- +20.0%
- Free cash flow
- +53.2%
- Total debt
- +2.74%
Quarter to September 2026, against a year earlier
2.93
0.13
−4.25%
Follow APYX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.72 | 2.89 | 3.37 | 1.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(56.85) | (282.18) | (56.41) | (66.04) | |
P/B ratio |
9.70 | 12.33 | 17.75 | 10.75 | |
Price to Tangible BV |
9.82 | 12.51 | 18.05 | 10.95 | |
EV/Sales |
2.95 | 3.12 | 3.65 | 2.13 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.48) | (22.14) | (21.08) | (15.39) | |
EV/FCF |
(17.10) | (19.38) | (19.32) | (14.24) | |
Quick Ratio |
4.15 | 4.65 | 4.41 | 3.74 | |
Current Ratio |
5.00 | 5.80 | 5.68 | 4.95 | |
Net Debt/EBITDA |
13.45 | (5.58) | (4.79) | (25.51) | |
Debt/Assets |
52.16% | 55.68% | 57.85% | 57.68% | |
Debt/Equity |
2.35 | 2.68 | 3.19 | 3.54 | |
Asset Turnover |
0.80 | 0.91 | 0.98 | 1.00 | |
Operating CF/Net income |
1.95 | 0.27 | 1.08 | 0.92 | |
Capex/Depreciation |
(1.24) | (0.30) | (0.34) | (1.42) | |
Interest Coverage |
0.01 | (0.67) | (1.30) | (0.40) | |
Research and Development Expense of Revenue |
4.93% | 6.12% | 5.71% | 6.05% | |
Selling, General and Administrative Expense of Revenue |
57.63% | 64.62% | 71.18% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.61% | 2.50% | 7.74% | 5.37% | |
Graham Net Nets |
0.04 | 0.03 | 0.02 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.71%) | (5.96%) | (4.45%) | (7.76%) | |
Free Cash Flow Yield |
(6.34%) | (5.57%) | (5.61%) | (8.24%) | |
Revenue per Share |
0.47 | 0.29 | 0.32 | 0.32 | |
Operating CF per Share |
(0.06) | (0.01) | (0.08) | (0.04) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.07) | (0.01) | (0.08) | (0.04) | |
Cash per Share |
0.77 | 0.71 | 0.63 | 0.59 | |
Shareholders Equity per Share |
0.36 | 0.30 | 0.25 | 0.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.30 | 0.25 | 0.23 | |
Free Cash Flow |
(2.80) | (0.63) | (3.56) | (1.90) | |
Working Capital |
46.77 | 45.35 | 43.80 | 42.97 | |
Capital Expenditures |
(0.27) | (0.06) | (0.07) | (0.26) | |
Net Current Asset Value |
6.46 | 4.86 | 3.17 | 2.21 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.13 | 12.20 | 12.43 | 13.93 | |
Average Payables |
2.84 | 2.47 | 2.54 | 3.37 | |
Average Inventory |
8.08 | 8.61 | 9.47 | 10.55 | |
Average Assets |
65.84 | 61.59 | 59.63 | 59.52 | |
Average Common Equity |
14.58 | 11.87 | 9.27 | 8.06 |
Columns are period end dates · fundamentals updated 5 Nov 2026